Quick answer
What is Tesamorelin?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Tesamorelin is a peptide, grouped on this site under GHRH analogues, and the 12 research records kept here are 5 from trials in people and 7 that do not state what kind of study it is.
The literature search returned 101 records. This site keeps 12 of them, which is 12 per cent of what came back.
What it is
This site puts it in the GHRH analogues group.
A growth hormone-releasing factor analogue acting at the GHRH receptor.[1]
Stated in the title of the cited 2010 Journal of Clinical Endocrinology and Metabolism trial report, which names it a growth hormone-releasing factor analog.
What kind of records
Several of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 5 of 12 indexed records are interventional human trials by their own assigned publication type.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 89 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab (2010). pmid:20554713